Impact of On-trial IGRT Quality Assurance in an International Adaptive Radiotherapy Trial for Participants with Bladder Cancer

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2024 Jul 28

PMID 39069085

Authors

Amanda Webster

Michael Francis

Hannah Gribble

Clare Griffin

Shaista Hafeez

Vibeke N Hansen

Rebecca Lewis

Helen McNair

Elizabeth Miles

Emma Hall

Robert Huddart

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Radiotherapy trial quality assurance (RT QA) is crucial for ensuring the safe and reliable delivery of radiotherapy trials, and minimizing inter-institutional variations. While previous studies focused on outlining and planning quality assurance (QA), this work explores the process of Image-Guided Radiotherapy (IGRT), and adaptive radiotherapy. This study presents findings from during-accrual QA in the RAIDER trial, evaluating concordance between online and offline plan selections for bladder cancer participants undergoing adaptive radiotherapy. RAIDER had two seamless stages; stage 1 assessed adherence to dose constraints of dose escalated radiotherapy (DART) and stage 2 assessed safety. The RT QA programme was updated from stage 1 to stage 2.

Materials And Methods: Data from all participants in the adaptive arms (standard dose adaptive radiotherapy (SART) and DART) of the trial was requested (33 centres across the UK, Australia and New Zealand). Data collection spanned September 2015 to December 2022 and included the plans selected online, on Cone-Beam Computed Tomography (CBCT) data. Concordance with the plans selected offline by the independent RT QA central reviewer was evaluated.

Results: Analysable data was received for 72 participants, giving a total of 884 CBCTs. The overall concordance rate was 83% (723/884). From stage 1 to stage 2 the concordance in the plans selected improved from 75% (369/495) to 91% (354/389).

Conclusion: During-accrual IGRT QA positively influenced plan selection concordance, highlighting the need for ongoing support when introducing a new technique. Overall, it contributes to advancing the understanding and implementation of QA measures in adaptive radiotherapy trials.

Citing Articles

Proton beam therapy image-guided radiotherapy training for RTTs - Experience from a single institution.

Kottakunnan J, Shoraka S, Dodd A, Kilkenny M, Petty S, Osborn K Tech Innov Patient Support Radiat Oncol. 2025; 33():100299.

PMID: 39850231 PMC: 11755385. DOI: 10.1016/j.tipsro.2024.100299.

Clinical implementation of RTT-only CBCT-guided online adaptive focal radiotherapy for bladder cancer.

Goudschaal K, Azzarouali S, Visser J, Admiraal M, Wiersma J, van Wieringen N Clin Transl Radiat Oncol. 2024; 50:100884.

PMID: 39559697 PMC: 11570400. DOI: 10.1016/j.ctro.2024.100884.

References

Webster A, Hafeez S, Lewis R, Griffins C, Warren-Oseni K, Patel E . The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance. Clin Oncol (R Coll Radiol). 2021; 33(7):461-467. DOI: 10.1016/j.clon.2021.02.009. View

McNair H, Franks K, van Herk M . On Target 2: Updated Guidance for Image-guided Radiotherapy. Clin Oncol (R Coll Radiol). 2021; 34(3):187-188. DOI: 10.1016/j.clon.2021.10.002. View

McNair H, Hafeez S, Taylor H, Lalondrelle S, McDonald F, Hansen V . Radiographer-led plan selection for bladder cancer radiotherapy: initiating a training programme and maintaining competency. Br J Radiol. 2015; 88(1048):20140690. DOI: 10.1259/bjr.20140690. View

Joyce E, Jackson M, Skok J, Rock B, McNair H . What do we want? Training! When do we want it? Now? A training needs analysis for adaptive radiotherapy for therapeutic radiographers. Radiography (Lond). 2023; 29(4):818-826. DOI: 10.1016/j.radi.2023.05.015. View

Taylor P, Miles E, Hoffmann L, Kelly S, Kry S, Moller D . Prioritizing clinical trial quality assurance for photons and protons: A failure modes and effects analysis (FMEA) comparison. Radiother Oncol. 2023; 182:109494. DOI: 10.1016/j.radonc.2023.109494. View

Gwynne S, Spezi E, Sebag-Montefiore D, Mukherjee S, Miles E, Conibear J . Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case. Br J Radiol. 2013; 86(1024):20120398. PMC: 3635785. DOI: 10.1259/bjr.20120398. View

Zhong H, Men K, Wang J, Soest J, Rosenthal D, Dekker A . The Impact of Clinical Trial Quality Assurance on Outcome in Head and Neck Radiotherapy Treatment. Front Oncol. 2019; 9:792. PMC: 6712430. DOI: 10.3389/fonc.2019.00792. View

Peters L, OSullivan B, Giralt J, Fitzgerald T, Trotti A, Bernier J . Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010; 28(18):2996-3001. DOI: 10.1200/JCO.2009.27.4498. View

Wills L, Maggs R, Lewis G, Jones G, Nixon L, Staffurth J . Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiat Oncol. 2017; 12(1):179. PMC: 5688711. DOI: 10.1186/s13014-017-0916-7. View

10.

Tyler J, Bernstein D, Seithel M, Rooney K, Petkar I, Miles E . Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer. Phys Imaging Radiat Oncol. 2021; 20:46-50. PMC: 8560997. DOI: 10.1016/j.phro.2021.10.003. View

11.

Hafeez S, Webster A, Hansen V, McNair H, Warren-Oseni K, Patel E . Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. BMJ Open. 2021; 10(12):e041005. PMC: 7780718. DOI: 10.1136/bmjopen-2020-041005. View

12.

Crane C, Winter K, Regine W, Safran H, Rich T, Curran W . Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009; 27(25):4096-102. PMC: 2734421. DOI: 10.1200/JCO.2009.21.8529. View

13.

Weber D, Tomsej M, Melidis C, Hurkmans C . QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol. 2012; 105(1):4-8. DOI: 10.1016/j.radonc.2012.08.008. View

14.

Ohri N, Shen X, Dicker A, Doyle L, Harrison A, Showalter T . Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst. 2013; 105(6):387-93. PMC: 3601950. DOI: 10.1093/jnci/djt001. View

15.

Webster A, McNair H, Hansen V, Lewis R, Patel E, Miles E . Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy. Tech Innov Patient Support Radiat Oncol. 2022; 21:31-35. PMC: 8841376. DOI: 10.1016/j.tipsro.2022.01.002. View

16.

Duhmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Ruhl U . Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol. 2001; 19(11):2905-14. DOI: 10.1200/JCO.2001.19.11.2905. View